Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma

被引：6

作者：

Wang, Ko-Fan ^{[1
]}

Chang, Cheng-Yu ^{[2
]}

Chang, Shih-Chieh ^{[1
]}

Liu, Yu-Chang ^{[1
]}

Yuan, Mei-Kang ^{[3
]}

Yang, Yuan-Hao ^{[1
]}

机构：

[1] Natl Yang Ming Univ Hosp, Dept Internal Med, Yilan 260, Taiwan

[2] Far Eastern Mem Hosp, Dept Chest Med, New Taipei City, Taiwan

[3] Natl Yang Ming Univ Hosp, Dept Radiol, Yilan 260, Taiwan

来源：

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION | 2013年 / 76卷 / 03期

关键词：

erlotinib; gefitinib; interstitial lung disease; CANCER;

D O I：

10.1016/j.jcma.2013.01.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced LLD. Here, we report a case of pulmonary adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD were treated successfully with the discontinuation of the tyrosine kinase inhibitors and high-dose intravenous corticosteroids. Copyright (C) 2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

引用

页码：173 / 175

页数：3

共 13 条

[1] Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
Ando, M
Okamoto, I
Yamamoto, N
Takeda, K
Tamura, K
Seto, T
Ariyoshi, Y
Fukuoka, M
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2549 - 2556
[2] Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia
Chang, Shih-Chieh
Chang, Cheng-Yu
Chen, Chiung-Yu
Yu, Chong-Jen
[J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1105 - 1106
[3] Chou Chun-Liang, 2010, Chang Gung Med J, V33, P100
[4] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets
Cohen, MH
Williams, GA
Sridhara, R
Chen, G
Pazdur, R
[J]. ONCOLOGIST, 2003, 8 (04) : 303 - 306
[5] Hotta K, 2008, J THORAC ONCOL, V3, P1050
[6] Severe acute interstitial pneumonia and gefitinib
Inoue, A
Saijo, Y
Maemondo, M
Gomi, K
Tokue, Y
Kimura, Y
Ebina, M
Kikuchi, T
Moriya, T
Nukiwa, T
[J]. LANCET, 2003, 361 (9352) : 137 - 139
[7] Gefitinib-induced interstitial lung disease showing improvement after cessation: Disassociation of serum markers
Kitajima, H
Takahashi, H
Harada, K
Kanai, A
Inomata, SI
Taniguchi, H
Saikai, T
Abe, S
[J]. RESPIROLOGY, 2006, 11 (02) : 217 - 220
[8] Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Kudoh, Shoji
Kato, Harubumi
Nishiwaki, Yutaka
Fukuoka, Masahiro
Nakata, Kouichiro
Ichinose, Yukito
Tsuboi, Masahiro
Yokota, Soichiro
Nakagawa, Kazuhiko
Suga, Moritaka
Jiang, Haiyi
Itoh, Yohji
Armour, Alison
Watkins, Claire
Higenbottam, Tim
Nyberg, Fredrik
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (12) : 1348 - 1357
[9] Fatal interstitial lung disease after erlotinib for non-small cell lung cancer
Lind, Joline S. W.
Smit, Egbert F.
Grunberg, Katrien
Senan, Suresh
Lagerwaard, Frank. J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1050 - 1053
[10] Gefitinib-induced lung injury successfully treated with high-dose corticosteroids
Seto, T
Seki, N
Uematsu, K
Tanigaki, T
Shioya, S
Koboyashi, T
Umemura, S
Eguchi, K
[J]. RESPIROLOGY, 2006, 11 (01) : 113 - 116

← 1 2 →